Market News & Trends
CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
MONTREAL, CANADA, – CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the launch of its Global Digital Pathology and AI Consortium,…
Evonik partners with evitria to accelerate early biologics development
Essen, Germany. Evonik has partnered with global antibody expression specialist evitria to offer a ready-to-use transient protein expression kit based on CHO cells for biopharmaceutical…
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Paris, The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with…
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
DURHAM, NC, Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing and preventing blindness from inherited retinal diseases, today announced the selection of a…
Gattefossé accelerates production ramp-up at its Lufkin facility with eight validated ingredients
Gattefossé, a leading provider of specialty ingredients and formulation solutions for the pharmaceutical and personal care industries, announces the successful validation of eight strategic ingredients…
Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis
TEL AVIV, ISRAEL, and Zug, Switzerland - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd and Polpharma Biologics International AG today announced…
Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
Essen, Germany. Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility. Over the next five years, the company…
Fonseca Biosciences Launches XTORO (finafloxacin otic suspension) 0.3% for Acute Otitis Externa
LONG BEACH TOWNSHIP, N.J. — Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, today announced the launch of XTORO (finafloxacin otic suspension),…
FUJIFILM Biotechnologies Selected in FDA PreCheck Pilot Program to Advance U.S. Drug Manufacturing
HOLLY SPRINGS, NC, FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced that its commercial-scale…
AustinPx Expands KinetiSol Technology Commercial Access through Thermo Fisher Scientific Collaboration
GEORGETOWN, Texas -- AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced its agreement…
Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability
HAVERHILL, England, Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, today…
BioPhorum Unites Regulators, Big Pharma and CDMOs to Accelerate Synthetic Molecule Innovation
LONDON - BioPhorum has announced the formation of the Synthetic Molecule Process Innovation Phorum, uniting an ecosystem of 20 leading organizations to urgently address the…
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Basel, Switzerland, – Lonza, a leading contract development and manufacturing organization (CDMO), today announced plans to enhance its drug-linker center of excellence and expand payload-linker…
Genmab and AbbVie Announce Topline Results for EPKINLY + lenalidomide in R/R DLBCL
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial met its primary objective, demonstrating statistically significant and clinically…
SUIC and VisionRenu Sign Strategic MOU to Accelerate AI Biotechnology, Precision Medicine, and U.S. Capital Market Expansion
NEW YORK, NY and TAIPEI, TAIWAN - SUIC Worldwide Holdings Ltd., a technology-enabled investment and business acceleration company, and VisionRenu Biomedical Technology Co., Ltd., a…
ten23 health obtains ATMP Manufacturing GMP Licenses from Swissmedic for its Basel and Visp facilities
Basel & Visp, Switzerland, ten23 health, a global contract development and manufacturing organization (CDMO) focused on sterile and biologic drug products, announced it has successfully…
AbbVie has announced it will acquire Apogee Therapeutics
AbbVie has announced it will acquire Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction, gaining access to zumilokibart, a late-stage immunology asset with…
ProMed Pharma Announces Second Dedicated Manufacturing Suite Agreement at Niagara Lane Facility
PLYMOUTH, MN, UNITED STATES, - ProMed Pharma a leading contract development and manufacturing organization (CDMO) specializing in long-acting injectable and implantable drug delivery systems, today…
Oryn Therapeutics Advances Next Phase of Orynotid Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
LOS ANGELES, CA – Oryn Therapeutics, a biotechnology company developing a novel class of immune-reprogramming macrocyclic peptides, today announced a series of strategic developments supporting…
Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
Oxford, UK, and San Jose, California, – Oxford BioTherapeutics (“OBT”), a clinical-stage oncology company specialising in proteomics-driven target discovery for antibody-based therapies enabled by its OGAP-Verify platform,…
